Clinical response to long term enzyme replacement treatment in children, adolescent and adult patients with Hunter syndrome;Respuesta clinica al tratamiento prolongado con terapia de reemplazo enzimático en niños, adolescentes y adultos con Síndrome de Hunter

Medicina Clinica

Volumn 145, Issue 9, 2015, Pages 392-398

  Dalmau Serra, Jaime ^a   Vitoria Miñana, Isidro ^a   Calderón Fernández, Rafael ^a   Cortell Aznar, Isidoro ^a  

^a HOSPITAL INFANTIL LA FE   (Spain)

Author keywords

Adolescents; Adults; Airway obstruction; Carpal tunnel syndrome; Children; Enzyme replacement treatment (ERT); Glycosaminoglycans (GAG); Hunter Outcome Survey (HOS); Hunter syndrome; Idursulfase; Mucopolysaccharidoses; Splenomegaly

Indexed keywords

GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE;

ADOLESCENT; ADULT; ARTICLE; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR SYMPTOM; CARPAL TUNNEL SYNDROME; CHILD; CLINICAL ARTICLE; CLINICAL PRACTICE; ENZYME REPLACEMENT; FACIES; FOLLOW UP; HUMAN; HUNTER SYNDROME; MALE; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; QUALITY OF LIFE; RETROSPECTIVE STUDY; SPLENOMEGALY; TREATMENT DURATION; TREATMENT RESPONSE; COMPLICATION; HEPATOMEGALY; MUCOPOLYSACCHARIDOSIS II; PATHOLOGY; RESPIRATION DISORDERS; SYMPTOM ASSESSMENT; TREATMENT OUTCOME; URINE; YOUNG ADULT;

ADOLESCENT; CARPAL TUNNEL SYNDROME; CHILD; ENZYME REPLACEMENT THERAPY; FACIES; GLYCOSAMINOGLYCANS; HEPATOMEGALY; HUMANS; IDURONATE SULFATASE; MALE; MUCOPOLYSACCHARIDOSIS II; QUALITY OF LIFE; RESPIRATION DISORDERS; RETROSPECTIVE STUDIES; SPLENOMEGALY; SYMPTOM ASSESSMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84944354998     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2015.06.015     Document Type: Article

References (31)

1. E.F. Neufeld, and J. Muenzer The mucopolysaccharidoses C.R. Scriver, The metabolic and molecular bases of inherited disease 2001 McGraw-Hill New York 3421 3452
2. M.M. Brands, I.M. Frohn-Mulder, M.L. Hagemans, W.C. Hop, E. Oussoren, W.A. Helbing, and et al. Mucopolysaccharidosis: cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI J Inherit Metab Dis 36 2013 227 234
3. C. Alcalde-Martín, J.M. Muro-Tudelilla, R. Cancho-Candela, L.G. Gutiérrez-Solana, G. Pintos-Morell, M. Martí-Herrero, and et al. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS) Eur J Med Genet 53 2010 371 377
4. B. Hoffmann, G. Schulze-Frenking, S. Al-Sawaf, M. Beck, and E. Mayatepek Hunter disease before and during enzyme replacement therapy Pediatr Neurol 45 2011 181 184
5. A.C. Brusius-Facchin, C.F. De Souza, I.V. Schwartz, M. Riegel, M.I. Melaragno, P. Correia, and et al. Severe phenotype in MPS II patients associated with a large deletion including contiguous genes Am J Med Genet 158A 2012 1055 1059
6. P.J. Meikle, J.J. Hopwood, A.E. Clague, and W.F. Carey Prevalence of lysosomal storage disorders JAMA 281 1999 249 254
7. F. Baehner, C. Schmiedeskamp, F. Krummenauer, E. Miebach, M. Bajbouj, C. Whybra, and et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany J Inherit Metab Dis 28 2005 1011 1017
8. J.E. Wraith, M. Scarpa, M. Beck, O.A. Bodamer, L. De Meirleir, N. Guffon, and et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy Eur J Pediatr 167 2008 267 277
9. S.A. Jones, Z. Almassy, M. Beck, K. Burt, J.T. Clarke, R. Giugliani, and et al. Mortality and cause of death in mucopolysaccharidosis type II - a historical review based on data from the Hunter Outcome Survey (HOS) J Inherit Metab Dis 32 2009 534 543
10. R. Martin, M. Beck, C. Eng, R. Giugliani, P. Harmatz, V.G. Muñoz, and et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome) Pediatrics 121 2008 377 386
11. J. Muenzer, J.E. Wraith, M. Beck, R. Giugliani, P. Harmatz, C.M. Eng, and et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) Genet Med 8 2006 465 473
12. J. Muenzer, M. Gucsavas-Calikoglu, S.E. McCandless, T.J. Schuetz, and A. Kimura A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome) Mol Genet Metab 90 2007 329 337
13. J. Muenzer, M. Beck, C.M. Eng, R. Giugliani, P. Harmatz, R. Martin, and et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome Genet Med 13 2011 95 101
14. J. Muenzer, M. Beck, R. Giugliani, Y. Suzuki, A. Tylki-Szymanska, V. Valayannopoulos, and et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey Genet Med 13 2011 102 109
15. A. Jurecka, Z. Krumina, Z. Zuber, A. Rózdzyńska-͆wiątkowska, A. Kłoska, B. Czartoryska, and et al. Mucopolysaccharidosis type II in females and response to enzyme replacement therapy Am J Med Genet A 158A 2012 450 454
16. E.A. Braunlin, J.M. Berry, and C.B. Whitley Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I Am J Cardiol 98 2006 416 418
17. V. Fesslová, P. Corti, G. Sersale, A. Rovelli, P. Russo, S. Mannarino, and et al. The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses Cardiol Young 19 2009 170 178
18. M. Scarpa, Z. Almássy, M. Beck, O. Bodamer, I.A. Bruce, L. De Meirleir, and et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease Orphanet J Rare Dis 6 2011 72
19. B.K. Burton, D.A. Whiteman HOS Investigators Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS) Mol Genet Metab 103 2011 113 120
20. B. Link, L.L. de Camargo Pinto, R. Giugliani, J.E. Wraith, N. Guffon, E. Eich, and et al. Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey Orthop Rev (Pavia) 2 2010 e16
21. C. Lampe, A. Atherton, B.K. Burton, M. Descartes, R. Giugliani, D.D. Horovitz, and et al. Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age JIMD Rep 14 2014 99 113
22. I. Wiklund, M. Raluy-Callado, D.E. Stull, Y. Jangelind, D.A. Whiteman, and W.H. Chen The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) Questionnaire: evaluation of measurement properties Qual Life Res 2012 10.1007/s11136-012-0196-5
23. M. Del Toro-Riera Follow-up of patients with Hunter syndrome: the Hunter Outcome Survey (HOS) registry Rev Neurol 1 2007 S13 S17
24. T. Okuyama, A. Tanaka, Y. Suzuki, H. Ida, T. Tanaka, G.F. Cox, and et al. Japan Elaprase® Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II) Mol Genet Metab 99 2010 18 25
25. A. Hirth, A. Berg, and G. Greve Successful treatment of severe heart failure in an infant with Hurler syndrome J Inherit Metab Dis 30 2007 820
26. J.E. Wraith, M. Beck, R. Lane, A. van der Ploeg, E. Shapiro, Y. Xue, and et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human α-l-iduronidase (laronidase) Pediatrics 120 2007 e37 e46
27. M. Scarpa, R. Barone, A. Fiumara, L. Astarita, G. Parenti, A. Rampazzo, and et al. Mucopolysaccharidosis VI: the Italian experience Eur J Pediatr 168 2009 1203 1206
28. B.K. Burton, and R. Giugliani Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls Eur J Pediatr 171 2012 631 639
29. V. Valayannopoulos, and F.A. Wijburg Therapy for the mucopolysaccharidoses Rheumatology (Oxford) Suppl. 5 2011 v49 v59
30. A.C. Brusius-Facchin, I.V. Schwartz, C. Zimmer, M.G. Ribeiro, A.X. Acosta, D. Horovitz, and et al. Mucopolysaccharidosis type II: identification of 30 novel mutations among Latin American patients Mol Genet Metab 111 2014 133 138
31. O.J. Lee, S.J. Kim, Y.B. Sohn, H.D. Park, S.Y. Lee, C.H. Kim, and et al. A study of the relationship between clinical phenotypes and plasma iduronate-2-sulfatase enzyme activities in Hunter syndrome patients Korean J Pediatr 55 2012 88 92